追踪澳大利亚青少年抑郁与焦虑症状的病程(CATS研究):一项基于人群的队列研究
在澳大利亚墨尔本基于人群的CATS队列中,1239名青少年从10岁随访至18岁,使用SMFQ和SCAS评估抑郁与焦虑症状。青少年期任何临床显著常见精神障碍症状的累积发生率为74%(95%CI 70-77),女性84%高于男性61%;抑郁和焦虑症状独立发生率分别为65%和58%,共病为48%,超过半数呈慢性病程,女性病程更差。
要点
- 青少年期任何临床显著常见精神障碍症状的累积发生率为74%(95%CI 70-77),女性84%高于男性61%。
- 抑郁与焦虑症状独立发生率分别为65%(62-68)和58%(55-62),共病发生率为48%(45-52)。
- 达阈值者中超过半数呈慢性病程(抑郁54%,焦虑52%),女性抑郁慢性病程64%高于男性37%。
核心结论
- 在这项当代多波次队列研究中,近四分之三的青少年报告了常见精神障碍症状,症状慢性化(即复发)的可能性高,亟需普遍性应对措施以解决这一重大公共卫生问题。
研究设计与样本
- 儿童至成人过渡研究(CATS)于2012年在澳大利亚墨尔本建立代表性青少年队列,采用分层抽样招募43所学校,邀请全部2289名8-9岁学生参与。
- 1239名(54.1%)学生获得父母书面知情同意,自2012年至2019年每年随访一次,共十波。
- 本研究使用第3至10波(10至18岁)数据描述常见精神障碍症状的病程,缺失数据采用多重填补处理,一名有亲身经历的作者参与了研究与写作过程。
主要发现
- 青少年期任何临床显著常见精神障碍症状的累积发生率为74%(95%CI 70-77),女性为84%(81-88),男性为61%(55-66)。
- 临床显著抑郁症状和焦虑症状的独立发生率分别为65%(62-68)和58%(55-62),共病常见精神障碍的发生率为48%(45-52)。
- 两性青少年期抑郁症状和焦虑症状首次报告的估计平均年龄分别为14.1岁(95%CI 13.9-14.4)和13.6岁(3.3-13.9)。
- 10至18岁间达到任何常见精神障碍阈值的青少年中,超过半数呈慢性病程(抑郁54%[49-60];焦虑52%[47-58]),三分之一在任一后续波次达到完全缓解标准(抑郁30%[25-35];焦虑33%[27-39])。
- 女性青少年常见精神障碍病程始终估计较男性更差,例如女性抑郁症状慢性病程为64%(58-70),男性为37%(26-48)。
关键数值与推荐
- 抑郁症状采用13条目简版情绪与感受问卷(SMFQ)自评过去2周情况,阈值分12分及以上提示临床相关症状。
- 焦虑症状采用8条目简版Spence儿童焦虑量表(SCAS)自评过去2周情况,阈值分11分及以上提示临床相关症状。
- 任何常见精神障碍定义为存在临床相关抑郁症状或焦虑症状;共病常见精神障碍定义为同时报告临床显著焦虑和抑郁症状。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adolescent mental health appears to be in crisis, yet few studies have comprehensively charted the course of common mental disorders (CMDs; depression and anxiety) across this key life stage. We aimed to describe the course of CMD symptoms in adolescence by summarising annual prevalence, cumulative incidence, and course for depression and anxiety, both separately and as comorbid CMDs, by sex assigned at birth in a contemporary Australian cohort. METHODS: The Child to Adult Transition Study (CATS) was established in 2012 to form a representative cohort of adolescents in Melbourne, VIC, Australia. 43 schools were recruited using a stratified sampling approach, and all 2289 students aged 8-9 years were invited to participate. 1239 (54·1%) students obtained parental written informed consent and were followed up annually from 2012 to 2019 for a total of ten waves. Data from waves 3-10 (ages 10 to 18 years) were used for the current study and analysed to describe the course of symptoms of CMDs across adolescence. Primary measures of interest were clinically relevant depressive symptoms, clinically relevant anxiety symptoms, and any CMD (clinically relevant depressive or anxiety symptoms) at waves 3-10. A secondary measure of interest was comorbid CMDs (concurrent reporting of clinically significant anxiety and depressive symptoms) at waves 3-10. Depressive symptoms in the past 2 weeks were self-reported using the 13-item validated Short Mood and Feelings Questionnaire (SMFQ) at each wave, with a threshold score of 12 or more indicating clinically relevant symptoms. Anxiety symptoms in the past two weeks were self-reported using an 8-item shortened version of the Spence Children's Anxiety Scale (SCAS) at each wave, with a threshold score of 11 or higher indicating clinically relevant symptoms. The course of CMDs was described using annual prevalence, cumulative incidence for depression and anxiety, separately and combined. Missing data were handled via multiple imputation. An author with lived experience was involved in the research and writing process. FINDINGS: Of the 1239 adolescents who participated in the study, 667 (53·8%) were female and 572 (46·2%) were male. 769 (62·1%) of 1239 were classified as socioeconomically advantaged, 675 (66·4%) of the 1016 with available data had a mother whose highest level of education was vocational or tertiary, and 579 (70·7%) of the 819 participants with ethnicity data identified as Anglo-Celtic or European. Overall, incidence of any clinically significant CMD symptoms during adolescence was 74% (95% CI 70-77; 84% [81-88] for females and 61% [55-66] for males). Independently, incidences of clinically significant depressive symptoms and anxiety symptoms were 65% (62-68) and 58% (55-62), respectively. Incidence of comorbid CMD was 48% (45-52). The estimated mean ages of first report in adolescence for both sexes were 14·1 years (95% CI 13·9-14·4) and 13·6 years (3·3-13·9) for depressive and anxiety symptoms, respectively. Of those who reached the threshold score for any CMD between ages 10 and 18 years, over half had a chronic (three or more waves) course (depression 54% [49-60]; anxiety 52% [47-58]), and a third met criteria for full remission at any subsequent wave (depression 30% [25-35]; anxiety 33% [27-39]). Females were consistently estimated to have a worse course of adolescent CMDs compared with males (eg, 64% [58-70] of females had a chronic course of depressive symptoms vs 37% [26-48] of males). INTERPRETATION: In this contemporary multi-wave cohort study, almost three-quarters of adolescents reported CMD symptoms. The likelihood of chronicity of CMD symptoms (ie, recurrence) was high. Universal responses are urgently required to address this considerable public health problem. FUNDING: National Health and Medical Research Council of Australia and the Royal Children's Hospital Foundation.
引用
- Robson EM, Husin HM, Ghazaleh Dashti S, et al. Tracking the course of depressive and anxiety symptoms across adolescence (the CATS study): a population-based cohort study in Australia. Lancet Psychiatry. 2024. PMID: 39644904. doi:10.1016/S2215-0366(24)00361-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。